公开(公告)号：US20220277805A1

公开(公告)日：2022-09-01

申请号：US17631067

申请日：2020-07-30

Applicant: BioSkryb Genomics, Inc. ,  St. Jude Children's Research Hospital, Inc.

Inventor： Jay A.A. WEST ,  Charles GAWAD ,  Sivaraman NATARAJAN ,  Robert CARTER ,  Veronica GONZALES-PENA

IPC: G16B20/00 ,  C12N15/10 ,  C12Q1/6827 ,  C12N5/0781 ,  C12N15/11 ,  C12N9/22 ,  G16B30/10 ,  G16H10/40

Abstract: Provided herein are compositions and methods for accurate and scalable Primary Template-Directed Amplification (PTA) nucleic acid amplification and sequencing methods, and their applications for mutational analysis in research, diagnostics, and treatment. Such methods and compositions facilitate highly accurate amplification of target (or “template”) nucleic acids, which increases accuracy and sensitivity of downstream applications, such as Next-Generation Sequencing.

公开(公告)号：US20210128612A1

公开(公告)日：2021-05-06

申请号：US17119832

申请日：2020-12-11

Applicant: Regents of the University of Minnesota ,  The University of North Carolina at Chapel Hill ,  Albert-Ludwig Universitat Freiburg ,  St. Jude Children's Research Hospital, Inc.

Inventor： Bruce R. Blazar ,  Brent Koehn ,  Peter J. Murray ,  Jenny P. Y. Ting ,  Robert Zeiser ,  Jeff S. Miller

IPC: A61K35/15 ,  C12N5/0787 ,  C12N5/078 ,  A61P37/06 ,  A61K39/00 ,  A61K45/06 ,  C12N5/0786

Abstract: In one aspect, a method of treating a subject having or at risk of having graft-versus-host disease (GvHD) generally includes administering to the subject a plurality of myeloid-derived suppressor cells (MDSCs) effective to ameliorate at least one symptom or clinical sign of graft-versus-host disease compared to a suitable control subject. In another aspect, a method of treating a tumor in a subject generally includes administering to the subject an anti-tumor therapy and co-administering to the subject an inflammasome inciting agent in an amount effective to increase inflammasome activation of MDSCs sufficiently to reduce suppressor function of the MDSCs.

公开(公告)号：US20210061788A1

公开(公告)日：2021-03-04

申请号：US16958022

申请日：2018-12-26

Applicant: ST. JUDE CHILDREN'S RESEARCH HOSPITAL, INC. ,  COA THERAPEUTICS, INC.

Inventor： Richard E. LEE ,  Rajendra P. TANGALLAPALLY ,  Charles O. ROCK ,  Suzanne JACKOWSKI ,  Anne V. EDWARDS ,  Mi Kyung YUN ,  Chitra SUBRAMANIAN ,  Robert ZAMBONI ,  T. Jagadeeswar REDDY

IPC: C07D403/04

Abstract: The present disclosure relates to chemical compounds that modulate pantothenate kinase (PanK) activity for the treatment of metabolic disorders (such as diabetes mellitus type II), neurologic disorders (such as pantothenate kinase-associated neurodegeneration), pharmaceutical compositions containing such compounds, and their use in treatment. This abstract is intended as a scanning tool for purposes of searching in the particular art and is not intended to be limiting of the present invention.

公开(公告)号：US10696972B2

公开(公告)日：2020-06-30

申请号：US15551659

申请日：2016-02-18

Applicant: St. Jude Children's Research Hospital, Inc.

Inventor： Stanislav S. Zakharenko ,  Jay A. Blundon

IPC: A01N43/04 ,  A61K31/70 ,  C12N15/113 ,  A61K31/713 ,  A61K31/7072 ,  A61K31/7105 ,  A61K31/416 ,  A61K31/4545 ,  G09B5/00 ,  G09B19/00

Abstract: The invention is directed to a method for improving learning and/or memory (e.g., auditory, visual, somatosensory or motor) in adults and children of an age which is beyond the early critical period for learning, said method comprising inhibiting (i) ecto-5′-nucleotidase (Nt5e, aka CD73) or (ii) A1 adenosine receptor (A1R, aka Adora1) expression or function in the brain. The invention is also directed to a method for treating learning and memory defects and neurological diseases associated with an abnormal auditory, visual, or somatosensory perception by inhibiting Nt5e or A1R expression or function in the brain.

公开(公告)号：US10011589B2

公开(公告)日：2018-07-03

申请号：US15125451

申请日：2015-03-12

Applicant: BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM ,  ST. JUDE CHILDREN'S RESEARCH HOSPITAL, INC.

Inventor： Richard E. Lee ,  Philip T. Cherian ,  Julian G. Hurdle ,  Xiaoqian Wu

IPC: C07D403/14 ,  C07D403/12 ,  C07D403/06

CPC classification number: C07D403/14 ,  C07D403/06 ,  C07D403/12

Abstract: Compounds for the treatment of bacterial and parasitic infections which are hybrid compounds of compounds having antibacterial or antiparasitic activity and compounds that decrease the absorption of the hybrid compound from the gastrointestinal tract. The compounds are preferably for use against C. difficile infections and comprise a hybrid molecule of an anti-C. difficile compound such as a nitroimidazole and a tetramic acid derivative.

公开(公告)号：US20180135015A1

公开(公告)日：2018-05-17

申请号：US15857268

申请日：2017-12-28

Applicant: ST. JUDE CHILDREN'S RESEARCH HOSPITAL, INC. ,  NATIONAL UNIVERSITY OF SINGAPORE

Inventor： Dario Campana ,  Yu-Hsiang Chang

IPC: C12N5/0783 ,  C07K14/705 ,  C12N5/00 ,  A61K35/17 ,  C07K14/725

CPC classification number: C12N5/0646 ,  A61K35/17 ,  A61K38/00 ,  C07K14/705 ,  C07K14/7051 ,  C07K14/7056 ,  C07K2319/00 ,  C07K2319/70 ,  C12N5/0087 ,  C12N2510/00

Abstract: The invention provides a chimeric receptor comprising NKG2D, DAP10 and CD3 zeta. Also disclosed is a composition comprising this chimeric receptor and methods for making and using it to enhance the cytotoxicity and antitumor capacity of NK cells. The invention also encompasses methods for use of NKG2D-DAP10-CD3 zeta polypeptides, vectors and cells in methods for treating cancer and other proliferative disorders, as well as infectious diseases.

公开(公告)号：US20180135013A1

公开(公告)日：2018-05-17

申请号：US15857147

申请日：2017-12-28

Applicant: ST. JUDE CHILDREN'S RESEARCH HOSPITAL, INC. ,  NATIONAL UNIVERSITY OF SINGAPORE

Inventor： Dario Campana ,  Yu-Hsiang Chang

IPC: C12N5/0783 ,  C07K14/705 ,  C12N5/00 ,  A61K35/17 ,  C07K14/725

CPC classification number: C12N5/0646 ,  A61K35/17 ,  A61K38/00 ,  C07K14/705 ,  C07K14/7051 ,  C07K14/7056 ,  C07K2319/00 ,  C07K2319/70 ,  C12N5/0087 ,  C12N2510/00

Abstract: The invention provides a chimeric receptor comprising NKG2D, DAP10 and CD3 zeta. Also disclosed is a composition comprising this chimeric receptor and methods for making and using it to enhance the cytotoxicity and antitumor capacity of NK cells. The invention also encompasses methods for use of NKG2D-DAP10-CD3 zeta polypeptides, vectors and cells in methods for treating cancer and other proliferative disorders, as well as infectious diseases.

公开(公告)号：US20180057563A1

公开(公告)日：2018-03-01

申请号：US15802968

申请日：2017-11-03

Applicant: St. Jude Children's Research Hospital, Inc.

Inventor： Dario Campana ,  Chihaya Imai

IPC: C07K14/705 ,  C07K14/725 ,  C07K16/28 ,  C07K14/47 ,  C12N5/0783 ,  A61K39/395

CPC classification number: C07K14/70578 ,  A61K39/395 ,  C07K14/47 ,  C07K14/7051 ,  C07K14/70517 ,  C07K16/2866 ,  C07K16/2878 ,  C07K16/2896 ,  C07K2319/32 ,  C12N5/0646 ,  C12N2501/23 ,  C12N2502/11 ,  C12N2502/99

Abstract: The present invention relates to a chimeric receptor capable of signaling both a primary and a co-stimulatory pathway, thus allowing activation of the co-stimulatory pathway without binding to the natural ligand. The cytoplasmic domain of the receptor contains a portion of the 4-1BB signaling domain. Embodiments of the invention relate to polynucleotides that encode the receptor, vectors and host cells encoding a chimeric receptor, particularly including T cells and natural killer (NK) cells and methods of use.

公开(公告)号：US09605049B2

公开(公告)日：2017-03-28

申请号：US14301122

申请日：2014-06-10

Applicant: St. Jude Children's Research Hospital, Inc.

Inventor： Dario Campana ,  Chihaya Imai

IPC: C07K14/705 ,  C07K16/28 ,  C12N5/0783 ,  A61K39/395 ,  C07K14/47 ,  C07K14/725

CPC classification number: C07K14/70578 ,  A61K39/395 ,  C07K14/47 ,  C07K14/7051 ,  C07K14/70517 ,  C07K16/2866 ,  C07K16/2878 ,  C07K16/2896 ,  C07K2319/32 ,  C12N5/0646 ,  C12N2501/23 ,  C12N2502/11 ,  C12N2502/99

Abstract: The present invention relates to a chimeric receptor capable of signaling both a primary and a co-stimulatory pathway, thus allowing activation of the co-stimulatory pathway without binding to the natural ligand. The cytoplasmic domain of the receptor contains a portion of the 4-1BB signaling domain. Embodiments of the invention relate to polynucleotides that encode the receptor, vectors and host cells encoding a chimeric receptor, particularly including T cells and natural killer (NK) cells and methods of use.

公开(公告)号：US20160347762A1

公开(公告)日：2016-12-01

申请号：US15024549

申请日：2014-09-29

Applicant: ST. JUDE CHILDREN'S RESEARCH HOSPITAL, INC.

Inventor： Richard E. Lee ,  Samanthi L. Waidyarachchi ,  David F. Bruhn ,  Jiuyu Liu ,  Zhong Zheng ,  Jason W. Rosch

IPC: C07D493/04 ,  A61K45/06 ,  A61K9/00 ,  A61K31/4433 ,  A61K31/381 ,  A61K31/497 ,  A61K31/4178 ,  A61K31/428 ,  A61K31/4045 ,  A61K31/4025 ,  A61K31/5377 ,  A61K31/357 ,  A61K31/427

CPC classification number: C07D493/04 ,  A61K9/0019 ,  A61K31/357 ,  A61K31/381 ,  A61K31/4025 ,  A61K31/4045 ,  A61K31/4178 ,  A61K31/427 ,  A61K31/428 ,  A61K31/4433 ,  A61K31/497 ,  A61K31/5377 ,  A61K45/06

Abstract: The invention relates to aryl substituted aminomethyl spectinomycin analogs, derivatives thereof, and related compounds, which are useful as anti-bacterial agents; methods for making the compounds; pharmaceutical compositions comprising the compounds; and methods of treating anti-bacterial infections using the compounds and compositions.

Abstract translation: 本发明涉及可用作抗菌剂的芳基取代氨基甲基壮观霉素类似物，其衍生物和相关化合物; 制备化合物的方法; 包含该化合物的药物组合物; 以及使用该化合物和组合物治疗抗菌感染的方法。